Trial reportClinical journal of the American Society of Nephrology : CJASN2011
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Blood pressure lowering efficacy of renin inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.Heart and vessels · 2013Trial
- Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.Clinical and experimental nephrology · 2013Trial
- The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.PloS one · 2013Trial
- [Inhibition of the renin-angiotensin-aldosterone system].Der nephrologe · 2022Review
- Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!Reviews of physiology, biochemistry and pharmacology · 2021Review
- Antihypertensive agents: a long way to safe drug prescribing in children.Pediatric nephrology (Berlin, Germany) · 2020Review
- Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence.Frontiers in physiology · 2020Review
- Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.Drugs · 2016Review
- Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.American journal of physiology. Renal physiology · 2015Review
- The effect of RAAS blockade on the progression of diabetic nephropathy.Nature reviews. Nephrology · 2014Review
- Direct renin inhibition in chronic kidney disease.British journal of clinical pharmacology · 2013Review
- Direct renin inhibition--a promising strategy for renal protection?Medical science monitor : international medical journal of experimental and clinical research · 2013Review
- Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?Drugs in context · 2013Review
- Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index.Journal of drug assessment · 2013Article
- Diabetic nephropathy.Clinical medicine (London, England) · 2012Article
- Transplantation: 5-year benefits of rituximab for ABO-mismatched renal grafts.Nature reviews. Nephrology · 2011Article
- Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease.American journal of cardiovascular disease · 2011Article
- Clinical Practice Guidelines. Management of Hypertension in Tunisian Adults.La Tunisie medicaleArticle
- Improvements in the Management of Diabetic Nephropathy.The review of diabetic studies : RDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesElevated BP contributes to development and progression of proteinuria and decline in renal function in patients with type 2 diabetes. Our post hoc analysis assessed the baseline BP influence on the antiproteinuric effect in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In the AVOID study, 599 hypertensive type 2 diabetic patients with nephropathy received 6 months of aliskiren (150 mg force titrated to 300 mg daily after 3 months) or placebo added to losartan (100 mg) daily and optimal antihypertensive therapy. Changes in early morning urinary albumin:creatinine ratio and eGFR at week 24 were assessed by subgroups of baseline BP: Group A (prespecified target), <130/80 mmHg (n=159); Group B, <140/90 mmHg but ≥130/80 mmHg (n=189); and Group C (insufficient BP control), ≥140/90 mmHg (n=251).
resultsMean baseline BP (mmHg) levels for Groups A, B, and C were 120/71, 133/78, and 145/81, respectively. BP during the trial was nearly identical to baseline levels in all groups. The antiproteinuric effects of aliskiren were consistent across subgroups of baseline BP (19 to 22% reduction versus placebo). In Group C, the decline in eGFR was significantly lower with aliskiren than with placebo (P=0.013).
conclusionsAliskiren (300 mg) added to losartan (100 mg) plus optimal antihypertensive therapy provides antiproteinuric effects independent of BP in patients with type 2 diabetes and nephropathy. Renal function was better preserved with aliskiren in patients with insufficient BP control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.